Stifel Maintains Hold on TransMedics Group, Lowers Price Target to $75

Benzinga Newsdesk www.benzinga.com Negative 79.7%

Neg 79.7% Neu 0% Pos 0%

Stifel analyst Tom Stephan maintains TransMedics Group (NASDAQ:TMDX) with a Hold and lowers the price target from $85 to $75.